Single-inhaler tripleversusdual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety

Tweetable abstract

A real-world study supports the new 2023 GOLD recommendation that single-inhaler triple therapy be reserved for group E and other exacerbating COPD patients with blood eosinophils count >300, otherwise it is not more effective and is riskier than LAMA-LABA https://bit.ly/3NpWtZC